Targeted Medical Pharma Exhibits at the 2011 JFPS in Dallas, Texas
Los Angeles, CA, November 14, 2011
Targeted Medical Pharma CEO, Dr. William Shell, at the 2011 JFPS.
Targeted Medical Pharma Inc. which develops and sells medical food products through its subsidiary Physician Therapeutics, exhibited product information and technology related to its medical foods addressing pain management and sleep disorders related to Post Traumatic Stress Disorder to over 2000 active and retired United States Military pharmacists, service men and women at the Joint Forces Pharmacy Seminar in Dallas, Texas from October 31-November 3, 2011. Other exhibitors included Takeda, Teva Neuroscience, Pfizer, GlaxoSmithKilne, Endo Pharmaceuticals and Express Scripts.
About Targeted Medical Pharma, Inc.
Targeted Medical Pharma, Inc. is a specialty pharmaceutical company that develops and sells nutrient- and pharmaceutical-based therapeutic systems for the nutritional management of chronic disease. The Company strives to optimize patient care with proprietary medical food products, as well as generic and branded pharmaceuticals it distributes through its subsidiary company, Physician Therapeutics. For additional information, please visit www.tmedpharma.com or www.ptlcentral.com
Company Contact
Marcus Charuvastra
Director of Marketing and Distributor Relations
(310) 474-9809
marcusch@ptlcentral.com
Targeted Medical Pharma Awarded $733,429.00 in Qualifying New Therapeutic Discovery Grants
Grants Cover Theramine® , Sentra PM®, Sentra AM® and GABAdone®
Los Angeles, CA, Nov. 1, 2010 /Targeted Medical Pharma Inc. a Specialty Pharma company developing proprietary medical food products distributed through subsidiary Physician Therapeutics announced it has been awarded $733,429.00 in government grants. Under the recently enacted Patient Protection and Affordable Care Act, cash grants were awarded to Qualifying Therapeutic Discovery Projects that showed significant potential in producing new and cost-saving therapies, support job growth and increase U.S. competitiveness. Grants were awarded through a competitive application process supervised by the National Institutes of Health. All three of the Company’s applications were awarded. The first involved the reduction of gastrointestinal hemorrhage by Theramine associated with treatment of back pain syndromes. The second involves reduction of the side effects associated with sleep disorders in the elderly with Sentra PM and GABAdone, and the third addresses a safe and effective treatment for symptoms of Gulf War Illness with Sentra PM and Sentra AM. The Company will be able to expand the growth of these and other innovative products with these funds.
Download Press Release
Double-Blind Clinical Trial of Theramine Published in the American Journal of Therapeutics
Read article “Double-Blind Clinical Trial of Theramine Published in the American Journal of Therapeutics” here.
In January of 2009 Physician Therapeutics, a wholly owned subsidiary of Targeted Medical Pharma Inc., initiated A Double Blind randomized controlled trial of single dose Naproxen and an amino acid Medical Food Theramine for the treatment of low back pain. Using 10 national sites over a 28 day period, this study consisted of 127 patients with established back pain. The trial concluded in June of 2009, and the study will be published by the American Journal of Therapeutics in November 2010.